MimiVax

MimiVax, Inc. is a clinical-stage biotechnology company developing SurVaxM, a survivin-targeted vaccine therapy for glioblastoma and other cancers. SurVaxM aims to revolutionize brain tumor treatment by stimulating the patient's immune response to control tumor growth and prevent recurrence. The therapy's potential extends to various cancers due to survivin's widespread presence.

Buy Funded Startups lists

Funding Round:

Funding Amount:

Date: 09-Jan-2024

Investors: Brain Tumor Investment Fund (BTIF), Sontag Innovation Fund, LLC, MEDA Angels, LLC, Varia Ventures, private investors

Markets: Biotechnology, Oncology, Immunotherapy, Drug Discovery

HQ: Buffalo, New York, United States

Founded: 2011

Website: https://www.mimivax.com/

LinkedIn: https://www.linkedin.com/company/mimivax

Twitter: https://twitter.com/MimiVax_Inc

Instagram: